
After presenting data at ESMO this past weekend, Tango Therapeutics believes that adding PRMT5 to RAS inhibitors represents the 'next chapter' in today's pancreatic cancer revolution (and beyond)
President and CEO Malte Peters summarizes the ESMO data for vopemetistat, which was in second and third line pancreatic cancer in combination with daraxonrasib, and discusses plans for a phase 3 in first line (plus the regulatory path for later lines as well). Additionally, he discusses using PRMT5 inhibition in lung cancer and GBM.
Publisher
BiotechTV - News
Link
podcasters.spotify.com/pod/show/biotechtv4/episodes/After-presenting-data-at-ESMO-this-past-weekend--Tango-Therapeutics-believes-that-adding-PRMT5-to-RAS-inhibitors-represents-the-next-chapter-in-todays-pancreatic-cancer-revolution-and-beyond-e3rbt21
Published
October 29, 2026
Duration
21 min
Format
Podcast
Category
Issues · Science
Source
RSS feed
Host
BiotechTV
BiotechTV - News
@biotechtvnews
#tangotherapeuticsbelieves #rasinhibitorsrepresents #todayspancreaticcancer #lifesciences
